A Phase 4 interventional study of HTX-011 and Bupivacaine Hydrochloride in Postoperative Pain, Total Shoulder Arthroplasty and Multimodal Analgesia, sponsored by Heron Therapeutics. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Heron Therapeutics · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.
Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 310th largest by enrollment, is one of 31 that started in 2021, is one of 133 in phase 4, and was the 283rd registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Wah Medical college , POF hospital · Sites in Pakistan
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
Erkan Gol · Sites in Turkey
Ages 18+ · Women only
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
364 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 57 · Phase 3 53 · Phase 4 133
First in 2004; this study’s year is marked. 31 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 364 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 364 have an industry lead sponsor. The 10 most frequent:
Heron Therapeutics is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 12 (86%) have results posted.
20 studies in Pain, Postoperative by Heron Therapeutics: none open now, 1 under way, none of them phase 3. Of 18 finished, 16 (89%) have results posted.
Among the 20 studies in Pain, Postoperative by Heron Therapeutics, this one is the 17th largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 4, and was the 19th registered.
Heron Therapeutics’s Pain, Postoperative studies by the year they started, since 2015.
22 of the studies testing bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07650760Wah Medical college , POF hospitalComparison of Intraperitoneal Bupivacaine and Saline Irrigation for Pain Relief After Laparoscopic Cholecystectomy | 2026-12 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT02381353Mayo ClinicExparel Injection for Postoperative Orbital Pain | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 364 studies testing bupivacaine in Pain, Postoperative, from their registry updates:
Among Heron Therapeutics’s 20 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
Cohort 1 (subjects undergoing total shoulder arthroplasty, TSA) of a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing different surgical procedures.
See also the separate record for the master study protocol (NCT05109312).
Subjects were randomized in a 2:1 ratio to have either HTX-011 400 mg/12 mg or bupivacaine HCl 100 mg administered into the surgical site prior to closure. Subjects and study site personnel performing postoperative safety and pharmacodynamic (PD) assessments were blinded to treatment assignments; however, unblinded study site staff were permitted to collect samples for pharmacokinetic (PK) analysis.
During surgery, in addition to study drug (HTX-011 or bupivacaine HCl), subjects could receive intravenous (IV) fentanyl, and all subjects were to receive a single dose of either IV morphine or IV hydromorphone just prior to the application of dermal sutures.
Subjects remained in the facility through 72 hours post-dose for safety, PK, and PD assessments. Subjects received a scheduled non-opioid multimodal analgesic (MMA) regimen throughout the 72-hour postoperative period consisting of oral (PO) acetaminophen 1 g every 8 hours (q8h) alternating with PO ibuprofen 400 mg q8h.
After discharge, subjects were to continue their scheduled MMA regimen through Day 7 and complete the daily diary to record opioid use through the Day 15 Visit.
PK sampling occurred through Day 7. For subjects with drains, all drainage fluid was to be collected and pooled over 12-hour intervals (±1 hour) through 72 hours post-dose for potential measurement of the concentrations of bupivacaine, meloxicam, and other ZYNRELEF components.
During the 72-hour postoperative period, subjects were to receive rescue medication only upon subject request for treating postoperative pain. Prior to administration of the first dose of rescue medication, if the subject had not already had at least 1 postoperative pain score assessed, then a numeric rating scale (NRS) of pain intensity at rest (NRS-R) score was to be obtained, followed by an NRS of pain intensity with activity (NRS-A) score.
If a subject had not received any opioids or received \<5 IV morphine milligram equivalents (MME; eg, \<10 mg of oxycodone) within 12 hours prior to discharge, the subject was not to receive an opioid prescription at discharge. If a subject had received ≥5 IV MME within 12 hours prior to discharge, the Investigator could provide the subject with a prescription for PO immediate-release oxycodone tablets: no more than twenty 5 mg immediate-release oxycodone, take 1 to 2 pills (5 to 10 mg) every 4 hours as needed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HTX-011 400 mg/12 mg via instillation + oral (PO) multimodal analgesic (MMA) regimen
Drug: HTX-011 · Drug: MMA regimen · Device: ZYNRELEF kit components for administration
Bupivacaine HCl 100 mg via injection + oral (PO) multimodal analgesic (MMA) regimen
Drug: Bupivacaine Hydrochloride · Drug: MMA regimen
Drug pages: Bupivacaine · Meloxicam
HTX-011 (bupivacaine/meloxicam) extended-release solution for instillation use, supplied in commercially available ZYNRELEF kits
Also known as: ZYNRELEF
bupivacaine HCl (without epinephrine) 0.25%
Drug pages: Acetaminophen · Ibuprofen
acetaminophen 1 g q8h every 8 hours (q8h) and ibuprofen 400 mg q8h, alternating the 2 medications so that an analgesic was taken approximately every 4 hours (q4h)
Also known as: acetaminophen, ibuprofen
ZYNRELEF kits include sterile, individually packaged components for administration, including vented vial spikes, Luer lock syringes, custom Luer lock applicators, and syringe tip caps.
Incidence of TEAEs
Incidence of treatment-emergent adverse events
Time frame: Through Day 15
Cmax
Maximum concentration of bupivacaine
Time frame: Through 144 hours
Tmax
Time of occurrence of maximum concentration of bupivacaine
Time frame: Through 144 hours
AUClast
Area under the concentration-time curve from Time 0 to the time of the last quantifiable concentration of bupivacaine
Time frame: Through 144 hours
AUCinf
Area under the concentration-time curve from Time 0 extrapolated to infinity of bupivacaine
Time frame: Through 144 hours
t½
Apparent terminal half-life of bupivacaine
Time frame: Through 144 hours
| Milestone | HTX-011 + MMA | Bupivacaine HCl + MMA |
|---|---|---|
| Started | 20 | 10 |
| Completed | 20 | 10 |
| Not completed | 0 | 0 |
Incidence of treatment-emergent adverse events
| Participants | HTX-011 + MMA | Bupivacaine HCl + MMA |
|---|---|---|
| Incidence of TEAEs | 18 | 7 |
Maximum concentration of bupivacaine
| ng/mL | HTX-011 + MMA | Bupivacaine HCl + MMA |
|---|---|---|
| Cmax | 372 ± 165 | 398 ± 288 |
Time of occurrence of maximum concentration of bupivacaine
| hours | HTX-011 + MMA | Bupivacaine HCl + MMA |
|---|---|---|
| Tmax | 20.12 (1.82 to 48.20) | 0.58 (0.50 to 2.77) |
Area under the concentration-time curve from Time 0 to the time of the last quantifiable concentration of bupivacaine
| h∙ng/mL | HTX-011 + MMA | Bupivacaine HCl + MMA |
|---|---|---|
| AUClast | 20500 ± 11900 | 4280 ± 1820 |
Area under the concentration-time curve from Time 0 extrapolated to infinity of bupivacaine
| h∙ng/mL | HTX-011 + MMA | Bupivacaine HCl + MMA |
|---|---|---|
| AUCinf | 20500 ± 11900 | 4320 ± 1820 |
Apparent terminal half-life of bupivacaine
| hours | HTX-011 + MMA | Bupivacaine HCl + MMA |
|---|---|---|
| t½ | 10.4 ± 2.46 | 7.51 ± 3.00 |
Collected over Through Day 15. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HTX-011 + MMA | 0/20 (0%) | 0/20 (0%) | 18/20 (90%) |
| Bupivacaine HCl + MMA | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Event | HTX-011 + MMA | Bupivacaine HCl + MMA |
|---|---|---|
| ConstipationGastrointestinal disorders | 6/20 | 0/10 |
| NauseaGastrointestinal disorders | 3/20 | 3/10 |
| DizzinessNervous system disorders | 5/20 | 2/10 |
| HeadacheNervous system disorders | 1/20 | 2/10 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/20 | 1/10 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/20 | 1/10 |
| VomitingGastrointestinal disorders | 1/20 | 1/10 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/20 | 1/10 |
| Oedema peripheralGeneral disorders | 0/20 | 1/10 |
| PyrexiaGeneral disorders | 0/20 | 1/10 |
| Age, Continuous(years) | HTX-011 + MMA | Bupivacaine HCl + MMA | Total |
|---|---|---|---|
| Mean | 67.9 ± 8.05 | 70.1 ± 9.61 | 68.6 ± 8.50 |
| Sex: Female, Male(Participants) | HTX-011 + MMA | Bupivacaine HCl + MMA | Total |
|---|---|---|---|
| Female | 5 | 3 | 8 |
| Male | 15 | 7 | 22 |
| Ethnicity (NIH/OMB)(Participants) | HTX-011 + MMA | Bupivacaine HCl + MMA | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 20 | 10 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | HTX-011 + MMA | Bupivacaine HCl + MMA | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 19 | 10 | 29 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | HTX-011 + MMA | Bupivacaine HCl + MMA | Total |
|---|---|---|---|
| United States | 20 | 10 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2021 to primary completion in Jul 2022, 8 months.
Results were first posted in Oct 2026, 4 years 3 months after primary completion.
Of 542 phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bupivacaine · Meloxicam